Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Akiva Mozes, Ziv Kop, Heidi Melin

Premium

The agricultural genomics firm Evogene has appointed Akiva Mozes and Ziv Kop to serve on its board of directors.

Mozes is chairman of Bazan Group's Oil Refinery, a member of the board of directors of Strauss Group, and he formerly was president and CEO of Israel Chemicals.

Kop is the founder and CEO of Go Capital, and he formerly was managing partner at Glenrock Israel and CEO of POC management consulting.


Accelrys said this week that its stockholders have elected Heidi Melin to serve on its board of directors until 2016. Melin is the chief marketing officer of Plex Systems, and she formerly was senior VP and chief marketing officer at Eloqua. She also worked in marketing and management at Taleo, Polycom, Hyperion, and Peoplesoft.

She will serve on the Accelrys board's human resources committee and governance and nominating committee.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.